Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott T Tagawa

Showing results (121-130 of 208) with videos related to

Pageof 21
Sort By:
Cancer|July 20, 2024
Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trialMichael J Morris, Johann de Bono, James Nagarajah, et al.
Future Oncology (London, England)|September 1, 2025
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapyPetros Grivas, Scott T Tagawa, Rohit K Jain, et al.
Eclinicalmedicine|October 21, 2024
Multivariable models of outcomes with [<sup>177</sup>Lu]Lu-PSMA-617: analysis of the phase 3 VISION trialKen Herrmann, Andrei Gafita, Johann S de Bono, et al.
British Journal of Cancer|January 20, 2022
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinomaKyrillus S Shohdy, Dario M Villamar, Yen Cao, et al.
Stroke|September 13, 2019
Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression ProfileBabak B Navi, Ryna Mathias, Carla P Sherman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor TherapyDaniel P Petrylak, Scott T Tagawa, Rohit K Jain, et al.
The Journal of Clinical Investigation|February 25, 2020
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancerHimisha Beltran, Alessandro Romanel, Vincenza Conteduca, et al.
The Journal of Urology|October 22, 2020
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical DataE David Crawford, Jason M Hafron, Scott T Tagawa, et al.
Cancer|November 20, 2013
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinomaPetros D Grivas, Stephanie Daignault, Scott T Tagawa, et al.
Future Oncology (London, England)|April 29, 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancerYohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.
Pageof 21

Showing results (121-130 of 208) with videos related to

Sort By:
Pageof 21
Cancer|July 20, 2024
Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trialMichael J Morris, Johann de Bono, James Nagarajah, et al.
Future Oncology (London, England)|September 1, 2025
A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapyPetros Grivas, Scott T Tagawa, Rohit K Jain, et al.
Eclinicalmedicine|October 21, 2024
Multivariable models of outcomes with [<sup>177</sup>Lu]Lu-PSMA-617: analysis of the phase 3 VISION trialKen Herrmann, Andrei Gafita, Johann S de Bono, et al.
British Journal of Cancer|January 20, 2022
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinomaKyrillus S Shohdy, Dario M Villamar, Yen Cao, et al.
Stroke|September 13, 2019
Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression ProfileBabak B Navi, Ryna Mathias, Carla P Sherman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor TherapyDaniel P Petrylak, Scott T Tagawa, Rohit K Jain, et al.
The Journal of Clinical Investigation|February 25, 2020
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancerHimisha Beltran, Alessandro Romanel, Vincenza Conteduca, et al.
The Journal of Urology|October 22, 2020
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical DataE David Crawford, Jason M Hafron, Scott T Tagawa, et al.
Cancer|November 20, 2013
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinomaPetros D Grivas, Stephanie Daignault, Scott T Tagawa, et al.
Future Oncology (London, England)|April 29, 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancerYohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.
Pageof 21